Elan Drug Technologies’ NanoCrystal® technology is truly one of the most successful drug delivery technology innovations in the past ten years. Designed to overcome issues associated with poor water solubility, ten years since its first filing with the FDA, it has gone on to achieve product in-market sales for clients in excess of $7.8B. Five products are now launched in over 100 territories worldwide incorporating this technology. Rapamune® (Wyeth) immunosuppressant, which was launched in 2001, eliminated need for refrigeration of tablet product and provided a 23% improvement in bioavailability. Emend® (Merck) was launched in 2003 for the treatment of nausea and vomiting with a 600% improvement in bioavailability, the product was successfully launched in Japan at end of 2009. TriCor® 145, which provided improved bioavailability and minimal food effect, was launched by Abbott in 2004. Megace ES®,, for cachexia in AIDS patients, was launched in 2005 with a 28% improvement in bioavailability, with a free from food effect. In August 2009, the first once- monthly schizophrenic injectable depot formulation, INVEGA® Sustenna™, was launched by Janssen using this technology.
Since 2001, 11 products using our technologies have been launched for our clients in over 100 countries worldwide, making us the most successful drug delivery company in the past decade. We believe more than any other drug delivery company we have developed superior, commercially successful technologies for our clients.
The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment